Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status |
Kang, Xing
(School of Life Sciences, Northwest University)
Chen, Rong (School of Life Sciences, Northwest University) Zhang, Jie (School of Life Sciences, Northwest University) Li, Gang (Department of Neurosurgery, Tangdu Hospital of the Fourth Military Medical University) Dai, Peng-Gao (School of Life Sciences, Northwest University) Chen, Chao (School of Life Sciences, Northwest University) Wang, Hui-Juan (School of Life Sciences, Northwest University) |
1 | Balss J, Meyer J, Mueller W, et al (2008). Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica, 116, 597-602. DOI ScienceOn |
2 | Bleeker FE, Molenaar RJ, Leenstra S (2012). Recent advances in the molecular understanding of glioblastoma. J Neuro-Oncol, 108, 11-27. DOI |
3 | Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-8. DOI |
4 | Chen QG, Zhang Z, Yang Q, et al (2012). The role of zinc transporter ZIP4 in prostate carcinoma. Urologic Oncol, 30, 906-11. DOI |
5 | Costello LC, Franklin RB (2013). A review of the current status and concept of the emerging implications of zinc and zinc transporters in the development of pancreatic cancer. Pancreat Disord Ther, Suppl 4. |
6 | Costello LC, Levy BA, Desouki MM, et al (2011). Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma. Cancer Biol Ther, 12, 297-303. DOI |
7 | Dubbink HJ, Taal W, van Marion R, et al (2009). IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology, 73, 1792-5. DOI |
8 | Ducray F, Marie Y, Sanson M (2009). IDH1 and IDH2 mutations in gliomas. New England J Med, 360, 2248-9. DOI |
9 | Duncan CG, Barwick BG, Jin G, et al (2012). A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res, 22, 2339-55. DOI |
10 | Franklin RB, Levy BA, Zou J, et al (2012). ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer. J Gastrointest Cancer, 43, 249-57. DOI |
11 | Franz MC, Anderle P, Burzle M, et al (2013). Zinc transporters in prostate cancer. Mol Aspects Med, 34, 735-41. DOI |
12 | Kambe T, Hashimoto A, Fujimoto S (2014). Current understanding of ZIP and ZnT zinc transporters in human health and diseases. Cell Mol Life Sci, 71, 3281-95. DOI |
13 | Kim I, Kim CH, Seo GH, et al (2008). Inhibitory effect of zinc on hypoxic HIF-1 activation in astrocytes. Neuroreport, 19, 1063-6. DOI |
14 | Krell D, Mulholland P, Frampton AE, et al (2013). IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol (London, England), 9, 1923-35. DOI |
15 | Wang J-B, Dong D-F, Wang M-D, et al (2014). IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in glioma cells in vitro and in vivo. Asian Pac J Cancer Prev, 15, 427-32. DOI |
16 | Li M, Zhang Y, Liu Z, et al (2007). Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. P Natl Acad Sci USA, 104, 18636-41. DOI |
17 | Lichten LA, Cousins RJ (2009a). Mammalian zinc transporters: nutritional and physiologic regulation. Ann Rev Nutr, 29, 153-76. DOI |
18 | Lonnerdal B (2007). Trace element transport in the mammary gland. Ann Rev Nutr, 27, 165-77. DOI |
19 | Lichten LA, Cousins RJ (2009b). Mammalian zinc transporters: nutritional and physiologic regulation. Ann Rev Nutr, 29, 153-76. DOI |
20 | Lin Y, Chen Y, Wang Y, et al (2013). ZIP4 is a novel molecular marker for glioma. Neuro Oncol, 15, 1008-16. DOI |
21 | Maret W (2013). Zinc and human disease. Met Ions Life Sci, 13, 389-414. DOI |
22 | Martin AB, Aydemir TB, Guthrie GJ, et al (2013). Gastric and colonic zinc transporter ZIP11 (Slc39a11) in mice responds to dietary zinc and exhibits nuclear localization. J Nutr, 143, 1882-8. DOI |
23 | Masica DL, Karchin R (2011). Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res, 71, 4550-61. DOI |
24 | Michalczyk A, Allen J, Blomeley R, et al (2002). Constitutive expression of hZnT4 zinc transporter in human breast epithelial cells. Biochem J, 364, 105-13. DOI |
25 | Nardinocchi L, Pantisano V, Puca R, et al (2010). Zinc downregulates HIF-1alpha and inhibits its activity in tumor cells in vitro and in vivo. PloS One, 5, 15048. DOI |
26 | Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12. DOI ScienceOn |
27 | Setty P, Hammes J, Rothamel T, et al (2010). A pyrosequencingbased assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagnostics, 12, 750-6. DOI |
28 | Watanabe T, Nobusawa S, Kleihues P, et al (2009). IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol, 174, 1149-53. DOI |
29 | Taylor KM, Vichova P, Jordan N, et al (2008). ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer cells. Endocrinology, 149, 4912-20. DOI |
30 | Turcan S, Rohle D, Goenka A, et al (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483, 479-83. DOI ScienceOn |
31 | Zhao S, Lin Y, Xu W, et al (2009). Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science, 324, 261-5. DOI ScienceOn |
![]() |